0001193125-26-134887
SEC filingKodiak Sciences reported widened GAAP operating and net losses for fiscal 2025, driven by increased pipeline and personnel expenses amid clinical advancement.
Kodiak has historically funded its operations primarily through issuance of common stock and sale of future royalties. The company’s prior losses and expected future losses will continue to have an adverse effect on its stockholders’ equity and working capital. Management notes that operating plans may change in the future, and additional capital will be required to meet associated operational needs and capital requirements. One or more future operational or market events may have a material adverse effect on the company’s liquidity and operating plans.